RxDoctor Payments Data

Jessica Sharp

Family · West Monroe, LANPI 1629164280

Payments from drug & device makers

$9,733in general payments, 2019–2025

Across 571 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • AstraZeneca$903
  • Takeda Pharmaceuticals U.S.A., Inc.$724
  • Novo Nordisk$657
  • Lilly USA, LLC$443
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$9,65299%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,733 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$124,546
Medicare patients
546
Services billed
5,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$101,713
EliquisApixaban83$70,988
MounjaroTirzepatide32$34,841
EntrestoSacubitril/Valsartan15$21,721
Tresiba Flextouch U-200Insulin Degludec16$19,297
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,822
MyrbetriqMirabegron14$13,950
JardianceEmpagliflozin16$13,776
JanumetSitagliptin Phos/Metformin Hcl14$11,273
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,907
XareltoRivaroxaban12$10,000
XyostedTestosterone Enanthate16$9,565
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,782
NamzaricMemantine Hcl/Donepezil Hcl13$6,760
Montelukast Sodium480$5,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$657$101,71384 claims
PfizerEliquis$378$70,98883 claims
Lilly USA, LLCMounjaro$443$34,84132 claims
AstraZenecaBreztri Aerosphere, Farxiga$903$15,71429 claims
GSKTrelegy Ellipta$376$14,82217 claims
Astellas Pharma US IncMyrbetriq$166$13,95014 claims
Boehringer IngelheimJardiance$324$13,77616 claims
MerckJanumet$195$11,27314 claims
Johnson & JohnsonXarelto$52$10,00012 claims
Antares Pharma, Inc.Xyosted$263$9,56516 claims
AbbVieNamzaric$1,474$6,76013 claims
Sanofi-aventis U.S. LLCLantus$28$2,89613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in West Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →